Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AF tweeted that Anavex paid Biogen for testing their drug when Anavex released the PR about the moa.
You saw that he took a stab at AF too by mentioning that BIIB is not a vendor that does tests for payment?
Yes he did say that. So my take away is he knows where he will get the money from and just can't say yet. 16 Million is good for 2 years and starting p2 trials for PK and Rett, and p2/3 for AD. He's getting money and it won't be from dilution. He said that the drug has already been manufactured for the Rett trial so I'm betting it starts soon. 3 months later, we find out if a2-73 works for Rett and off the p2/3 if it does.
Long story short, I see no reason to sell after this conference call.
Xena,
Remembering you talked about Takeda being a possible partner for the Asian market, Steffen Thomas used to work for Takeda. Also, before working there, he worked for a Company that Takeda bought out for $10B. Not saying that Anavex will get bought, just that there IS a connection.
Another sticky worthy post
There is a poison pill, dig deeper and you'll find it. There's a lot of authorized shares than can be released in such a scenario.
I hope the Dr. laughs at all offers of a buy out and offers partnership or nothing. Why sell out to BP when you have the most promising drug to help multiple cns diseases. I don't care about fast money, I'm in it for the long haul. 10-15 years could turn a measly $1000 into 6-7 digits if we have THE drug. Still a ways away and could lose everything too.
This looks like a shout out to Anavex and their trial design, no?
However, he said changes are needed in the design of clinical trials, especially for drugs intended to stop disease progression rather than treat symptoms. “Disease-modifying drugs act slowly and it’s hard to measure their effect, so selecting an optimal dose in a manageable sized trial is impossible,” he said. Consequently, sponsors have moved into large, costly, phase 3 (confirmatory) trials without knowing the correct dose. “I think that accounts for an enormous amount of failure over the last twenty years,” said Aisen.
Adding to that:
Axovant - 5HT6 receptor
Anavex - Sigma-1 receptor
When I re-read my comments and realize I don't have a clue what direction I'm going, I hit cancel post.
Its responses from 16 different patients. 2 patients had 2 comments.
Yes, but I'm more sympathetic for the patients. Glad to see that they finally put those types of comments in a presentation.
Slide 30 is a beautiful thing.
Documented patient comments
I was monitoring the site for changes too. Guess I didn't have enough coffee this am. Thanks
Yes and everything else is just noise to try and get you to sell your shares
Until they release bad data or prs, I don't know about you, but its been a long for me since I found out about this company over a year and a half ago.
That's what I was thinking this morning when I read that pr. LLY tryin to low ball US!!
Large being a number according to whom? Our own CEO said a p3 will have about 300 participants. Is 300 large enough for a p3 or are we so used to having thousands of participants that it has to have thousands before the statistics have any truth. After all, the we are getting guidance from the FDA.
Yep Kind of like a what did CTAD do, they aren't supposed to have released the abstract of BIIB, not mentioning that every abstract was "leaked". Then to top that by saying, since it was leaked, that is what spiked the stock, kind of insinuating that the data was good. Not a bash like last year (yet), but a pump for one of his babies.
Heres a phantasm of thought. Maybe, just maybe, BIIB is delaying the abstract till weekend so they won't drop 5-10 Billion. Then come Monday, they PR that they will partner with Anavex for a P3, using no more than a Billion they would have lost anyway.
I'm just happy that the tsunami watch here locally has been cancelled.
Happy trading everyone
Its because they've been fed a falseness that they believe to be true, which is that Amayloid plaques are the cause of Alz. Just like Aristotle during his time, we dare to be different. While everyone believes the earth is flat ( amyloid plaques cause Alzheimers), we are out to prove that the earth is actually round. I don't blame them too for their ignorance. Everyone fears what they don't understand.
True, but 99% of AD trials that target Plaques are trying to make that dead horse run to the finish line. Anavex already has a better safety profile than that of SOC. All it needs to do is keep either the same slope or better than soc and we have a winner. Then again, all of that data won't be taken seriously until its from a p3. All of this is just secondary data that will help design the next phase. Sink or sail into the sunset, I have my comfortable amount of $$ I'm willing to play long. Like 5-10+ year long.
Remember, No matter what, we are on to P3 next year as earlier prs stated.
IMO, BP don't want to partner, we will get grants to fund
I don't understand your insisting the company is only worth 2B when we are headed into a p3 in 2017 and you saw how much value EL lost when their p3 failed. Besides imo, that number was probably already offered and Missling laughed. Hence why we are in the sub $4 instead of where we should be.
For my fun play account. Robinhood. No fees to buy or sell wish a cash account. ?? I'm not a big investor. Just buy and hold. Figure if I can't go to Vegas, I'll bring Vegas to my phone.
I always put something in the mega bucks machine(avxl) and hopefully one day we all will hit our jackpot.
Never mind, it got hit on this second dip down
Why would my limit order at 3.71 get passed on the way down to 3.70?
Ahh, but didn't you see AF already show his hand about the data result? He took the stance of it doesn't matter WHAT it is because it's only 32 participants. It's not worth the paper it's written on.
Although everything was with guidance from the FDA, but hey, what do they know right, they don't work the THE st.
I have a gut feeling that some influencers short FOR BP.
One should know the different phases of trials and their purpose instead of listening to the short chirpers out there. Ph 3, which a pr already stated, will include a double blinded, placebo so on and so forth. A more realistic scam would be to take a failed drug for pennies on the dollar and making people believe you too have a possible medicine for Alz. All the while, knowing deep down that you have nothing.
#4 looks like it's needed because I just saw a news piece that the FDA approved a clinical trial to use extacy as a pill to help treat ptsd
I hope Anavex doesn't get gobbled up. That is a pretty short sighted view if the company is only bought for 1.5 B. I would vote no on a buyout and let my investment mature for 5 years. Who knows where it will be. Down, yes, it could lose 100% of its value. Up? just look at what a failed AZ drug did to Lilly last week. $8 Billion shed off of its value. In my opinion, all of those investors are looking for the next potential place to hedge their bets, and Anavex looks mighty good right now. Lets see how good in less than 2 weeks.
Here Ven69 fintel shows all the recent institutional buys and sells
https://fintel.io/so/us/avxl
New article for failure of solanezumab. Got Anavex as #1 in the comments so far. = )
I personally hope Missling doesn't sell at all or if he does that it'd be in the $5-$10B range. Approval of 2-73 would bring in ridiculous $$, then there is 3-71 right behind for the #2 punch. I'd love to see AVXL turn into Big Pharma itself and this one trial could help it get there.
I, for one, was waiting for sub 3 to add to my position. I did today at 2.90. One persons filth is another persons treasure. In due time, IMO, it'll turn into a shiny piece of coin and more than likely be repeating that tune on another stock.
"The next stage of clinical trials is in preparation for ANAVEX 2-73: a larger Phase 2/3 study as well as another Phase 2 in an orphan indication, and it could be Rett syndrome."
Did he say phase 2 orphan indication IS Rett or phase 2 in an orphan indication plus phase 2 in Rett?
Lucky you, I was and still am waiting for sub $3 before adding more. Maybe we get there maybe not. Either way.....patience.